Verteporfin-maker QLT to merge with Atrix

July 15, 2004

Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.